Financial giants have made a conspicuous bullish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals ALNY revealed 9 unusual trades.
Delving into the details, we found 44% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $251,500, and 5 were calls, valued at $247,425.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $145.0 to $175.0 for Alnylam Pharmaceuticals over the last 3 months.
Volume & Open Interest Development
In today's trading context, the average open interest for options of Alnylam Pharmaceuticals stands at 223.25, with a total volume reaching 73.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Alnylam Pharmaceuticals, situated within the strike price corridor from $145.0 to $175.0, throughout the last 30 days.
Alnylam Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALNY | PUT | SWEEP | NEUTRAL | 12/20/24 | $24.3 | $21.1 | $22.7 | $145.00 | $106.5K | 0 | 0 |
| ALNY | CALL | TRADE | BULLISH | 07/19/24 | $18.0 | $16.1 | $18.0 | $175.00 | $90.0K | 447 | 0 |
| ALNY | PUT | TRADE | BEARISH | 12/20/24 | $25.8 | $22.7 | $25.0 | $150.00 | $75.0K | 30 | 0 |
| ALNY | CALL | TRADE | BEARISH | 07/19/24 | $26.8 | $25.8 | $25.8 | $160.00 | $49.0K | 565 | 0 |
| ALNY | CALL | SWEEP | NEUTRAL | 06/21/24 | $18.0 | $17.0 | $17.01 | $145.00 | $44.2K | 209 | 15 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Following our analysis of the options activities associated with Alnylam Pharmaceuticals, we pivot to a closer look at the company's own performance.
Current Position of Alnylam Pharmaceuticals
- Trading volume stands at 207,796, with ALNY's price up by 1.73%, positioned at $159.13.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 50 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Alnylam Pharmaceuticals with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
